IPP Bureau
Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
By IPP Bureau - January 07, 2023
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).
Dabur India expects low to mid-single digit revenue growth for Q3 FY23
By IPP Bureau - January 07, 2023
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Zydus launches Topiramate Extended-Release Capsules
By IPP Bureau - January 07, 2023
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
By IPP Bureau - January 07, 2023
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
ANSSI Wellness inaugurates new spine health facility in Nashik
By IPP Bureau - January 07, 2023
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
By IPP Bureau - January 06, 2023
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Helix and QIAGEN to jointly develop and commercialize companion diagnostics for hereditary diseases
By IPP Bureau - January 06, 2023
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Provention Bio appoints Rita Jain to Board of Directors
By IPP Bureau - January 06, 2023
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Chindex Medical acquires 10 ViewRay MRIdian Systems for advanced cancer treatment
By IPP Bureau - January 06, 2023
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
PMBI launches Jan Aushadhi Chyawanprash Special
By IPP Bureau - January 06, 2023
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Mandaviya interacts with representatives of private medical colleges
By IPP Bureau - January 06, 2023
Seeks partnership between government and private medical colleges for providing superior medical education
Yaral Pharma launches diclofenac epolamine topical system 1.3%
By IPP Bureau - January 05, 2023
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Biocytogen and Hansoh Pharma announce an antibody license agreement
By IPP Bureau - January 05, 2023
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Applied Therapeutics partners with Advanz Pharma for commercialization of Govorestat in Europe
By IPP Bureau - January 05, 2023
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
PharmaEssentia sets up a new R&D facility in the Boston Area
By IPP Bureau - January 05, 2023
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
